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A significant stress faced by all
animals is the unpredictable cycle
of feeding and then starvation that
ensues between meals. Humans
solve this problem by storing
nutrients in forms that can be
used as energy sources during
periods of fasting. The driving
force that regulates this process is
insulin, a hormone released by the
β-pancreatic islet cells in response
to elevated levels of nutrients,
such as glucose in the blood
supply. Insulin binds to its
receptor on the major insulin
responsive tissues of the body
namely skeletal muscle, adipose
tissue and liver. This triggers the
activation of a signalling pathway
whose function is first to stimulate
the transport of nutrients, such as
glucose, amino acids and fatty
acids, from the blood supply to
these tissues and, secondly, to
promote the conversion of these
nutrients into storage
macromolecules, such as
glycogen, protein, and lipids.
Failure to regulate the uptake and
storage of nutrients efficiently
following feeding results in
diabetes, which is estimated to
affect ~2% of the world
population. Type 1 diabetes is
characterised by the failure to
synthesise insulin and affects
~10% of diabetics; it normally
occurs in childhood and can be
treated with daily injections of
insulin. In contrast, type 2
diabetes affects ~90% of
diabetics and usually occurs in
adults. In this form of diabetes the
target tissues become resistant to
the effects of insulin, presumably
because the insulin-signalling
pathway is impaired. Type 2
diabetes can only be moderately
controlled by regimes of poorly
effective drugs and nutritional
control. Patients suffering from
this form of diabetes invariably
suffer long-term complications
including kidney and heart
disease, loss of sight, and their life
expectancy is reduced on average
by 5–10 years.
Insulin signalling at the membrane
The binding of insulin to its tyrosine
kinase receptor on the outside
surface of cells induces the
receptor to phosphorylate itself at
several tyrosine residues located
inside the cell. This results in the
recruitment of a lipid kinase termed
PI 3-kinase to the plasma
membrane of cells, bringing it in
the vicinity of its physiological
substrate phosphatidylinositol (4,5)
bisphosphate (PtdIns(4,5)P2) which
it phosphorylates at the D3
position of the inositol ring to
generate PtdIns(3,4,5)P3 (Figure 1).
These events occur within the first
minute of insulin binding to its
receptor and result in a significant
increase in the concentration of
PtdIns(3,4,5)P3 in cells. The finding
that inhibitors of PI 3-kinase, or the
overexpression of dominant
negative mutants of this enzyme,
inhibit most of the cellular
responses to insulin, including
stimulation of glucose transport as
well as glycogen and protein
synthesis, established that
PtdIns(3,4,5)P3 is a key second
messenger in the insulin signalling
pathway.
A key effector of PtdIns(3,4,5)P3
in insulin signalling is a protein
kinase termed protein kinase B
(PKB), also known as Akt, of
which there are 3 closely related
isoforms. PKB has a pleckstrin
homology domain located at its
amino terminus, which binds to
PtdIns(3,4,5)P3. This results in
PKB becoming recruited from the
cytosol to the plasma membrane
where PtdIns(3,4,5)P3 is located.
The interaction of PKB with
PtdIns(3,4,5)P3 at the membrane
does not activate PKB directly,
but instead brings it close to two
other protein kinases that
Figure 1. Overview of the regulation of major metabolic responses in cells by insulin.
Binding of insulin to its receptor induces autophosphorylation at a number of tyrosine
residues. Certain residues are recognised by the phosphotyrosine-binding (PTB)
domain of adaptor proteins termed insulin receptor substrates (IRS), which are recruited
to the receptor at the cell membrane. The insulin receptor then phosphorylates IRS mol-
ecules at numerous tyrosine residues, some of which are recognised by the Src homol-
ogy 2 (SH2) domain of the p85 regulatory subunit of a lipid kinase, PI 3-kinase. The
catalytic subunit of PI 3-kinase, p110, then phosphorylates PtdIns(4,5)P2 at the plasma
membranes of cells to generate the second messenger PtdIns(3,4,5)P3 which stimulates
insulin-dependent processes. Binding of insulin to its receptor also causes it to phos-
phorylate the protein Cbl which is in a complex with the adaptor protein CAP. This
results in the Cbl–CAP complex being recruited to a region of the plasma membrane
termed a lipid raft. At this location Cbl interacts with the adaptor protein Crk which is
constitutively associated with the Rho-family guanine nucleotide exchange factor, C3G.
C3G then activates members of the GTP-binding protein family, TC10, which them-
selves activate unknown effector molecules to promote GLUT4 translocation. Dotted
arrows are steps of the pathway that have not yet been fully elucidated.
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phosphorylate PKB at Thr308 and
Ser473. It is these
phosphorylation events which
activate PKB. Thr308 is in the core
of the protein kinase catalytic
domain in a region known as the
activation loop or T-loop, while
Ser473 is located in a carboxy-
terminal non-catalytic region
known as the hydrophobic motif.
PKB is phosphorylated at Thr308
by the protein kinase 3-
phosphoinositide-dependent
protein kinase-1 (PDK1), which
like PKB has a PtdIns(3,4,5)P3
binding pleckstrin homology
domain. It is likely that the
colocalisation of PKB and PDK1
with PtdIns(3,4,5)P3 enables PDK1
to phosphorylate PKB at Thr308
(Figure 2). Despite several years of
intensive research, the identity of
the protein kinase(s) that
phosphorylates PKB at its
hydrophobic motif has not been
established, but the enzyme has
been provisionally termed PDK2.
Once activated, PKB
dissociates from the plasma
membrane and phosphorylates
numerous substrates in both the
cytoplasm and the nucleus, which
play important roles in regulating
insulin dependent processes. PKB
phosphorylates proteins at a
specific motif that requires two
arginine residues to be located 3
and 5 residues amino-terminal to
the site of PKB phosphorylation. It
is likely that only a few of the
physiological substrates of PKB
have thus far been identified.
One of these is another protein
kinase termed glycogen synthase
kinase-3 (GSK3), which is
inactivated following its
phosphorylation by PKB. One key
GSK3 substrate is glycogen
synthase, which catalyses the
final step in glycogen synthesis,
the conversion of UDP-glucose
into glycogen. Phosphorylation of
glycogen synthase by GSK3,
inhibits glycogen synthase.
Therefore, inactivation of GSK3 by
PKB results in dephosphorylation
of glycogen synthase through the
action of protein phosphatases
and hence the activation of
glycogen synthesis. There is also
some evidence that insulin
stimulates the dephosphorylation
of glycogen synthase by
activating a glycogen-associated
form of protein phosphatase-1.
However, the importance of this
pathway in activating glycogen
synthesis, and the branch of the
insulin-signalling pathway that
regulates this phosphatase,
remain to be determined. GSK3
also phosphorylates and inhibits a
guanine nucleotide exchange
factor, eIF2B, that controls the
initiation stage of protein
translation. Insulin induces the
dephosphorylation of eIF2B at the
site phosphorylated by GSK3,
thereby stimulating the synthesis
of protein from amino acids. Thus
insulin-dependent inactivation of
GSK3 underlies the insulin-
induced synthesis of glycogen
and protein (Figure 1).
Insulin inhibits lipid metabolism
in fat cells by decreasing cellular
concentrations of cyclic AMP in
adipocytes. This process appears
to be mediated by PKB via the
phosphorylation and activation of a
cAMP phosphodiesterase isoform,
PDE3B. In the heart PKB
phosphorylates and activates a
cardiac-specific form of 6-
phosphofructose 2-kinase, a rate-
limiting enzyme of glycolysis. This
stimulates ATP production in these
cells, which is required to fuel
increased cardiac output. PKB also
phosphorylates the Forkhead
family of transcription factors at
3 residues, thereby generating
strong interaction sites for the
14-3-3 family of scaffolding
proteins. The binding of 14-3-3
to Forkhead proteins triggers their
relocalisation from the nucleus
to the cytoplasm, away from their
nuclear targets. Although insulin
has profound effects on the
expression of many genes, it is
currently controversial whether
Forkhead transcription factors
mediate any of these effects.
Although it is likely that PI 3-kinase
and PKB regulate insulin-
dependent gene expression, the
evidence for this depends on non-
physiological experiments in
which constitutively active or
dominant negative forms of these
kinases have been overexpressed
in cells.
Other PDK1 targets
Insulin activates several other
protein kinases belonging to the
same subfamily of protein kinase
as PKB. These include p70
ribosomal S6 kinase (S6K), as well
as the serum and glucocorticoid
induced protein kinase (SGK). The
activation of S6K and SGK by
insulin is dependent on PI
3-kinase, and these enzymes
possess a similar activation loop
and hydrophobic motif to PKB.
PDK1 phosphorylates S6K and
SGK at their activation loop and an
as yet uncharacterised kinase
phosphorylates their hydrophobic
motif. Unlike PKB, S6K and SGK
do not have a pleckstrin homology
domain and cannot interact
directly with PtdIns(3,4,5)P3.
Although it is still not completely
understood how S6K and SGK
isoforms are activated by insulin,
recent evidence indicates that
PtdIns(3,4,5)P3 stimulates the
phosphorylation of the hydrophobic
motif of these enzymes by either
activating the hydrophobic motif
kinase or by inhibiting the
phosphatase that dephosphorylates
the hydrophobic motif. The
phosphorylation of the hydro-
phobic motif of S6K and SGK
isoforms in the absence of the
T-loop being phosphorylated does
not activate these enzymes, but
instead generates a PDK1 docking
site, enabling S6K and SGK to
interact with PDK1. This results in
S6K and SGK becoming phos-
phorylated at their activation loops
and hence activated (Figure 2).
S6K was the first insulin-
stimulated kinase to be
discovered, nearly 20 years ago,
but only 2 physiological
substrates of this enzyme have
been identified so far, namely the
ribosomal S6 protein and the
elongation factor 2 kinase.
Phosphorylation of ribosomal S6
protein stimulates the translation
of mRNAs that have poly-
pyrimidine tracts at their 5′ end,
and which are mainly ribosomal
proteins. This enhances the
biosynthesis of ribosomes whose
increased production is required
to cope with the increased rate of
protein synthesis stimulated by
insulin. Phosphorylation of
elongation factor 2-kinase inhibits
its activity, and results in
dephosphorylation of its only
known substrate, elongation
factor-2 (EF2); dephosphorylated
EF2 stimulates the elongation
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stage of protein synthesis.
Preliminary evidence suggests
that activation of SGK may play a
role in regulating salt retention in
the kidney. PDK1 also activates
protein kinase C isoforms; whilst it
has been reported that insulin
modestly activates certain PKC
isoforms, and this has been
proposed to play a role in
regulating glucose transport, it is
our opinion that the evidence on
which this conclusion is based is
not convincing.
Insulin stimulates glucose uptake
A key action of insulin is to
stimulate glucose uptake into
cells by inducing the
translocation of the glucose
transporter, GLUT4, from
intracellular storage sites to the
plasma membrane.
Overexpression of constitutively
activated mutants of PI 3-kinase
and PKB stimulates the
recruitment of GLUT4 to the cell
surface in the absence of insulin.
Moreover, mice lacking a specific
isoform of PKB termed PKBβ or
Akt2 are diabetic, and insulin-
stimulated glucose uptake in the
liver and muscle tissues of these
animals is impaired. Recent
studies by Saltiel and colleagues
suggest that another PI 3-kinase
independent pathway may
provide a second signal that
plays an important role in
permitting insulin to stimulate the
recruitment of GLUT4 to the
plasma membrane. In this
pathway, activated insulin
receptor directly phosphorylates
the proto-oncogene Cbl, which
activates the TC10 family of Rho
GTP-binding proteins. These
proteins then interact with




A key aim for future research is to
identify the hydrophobic motif
kinase that phosphorylates PKB,
S6K, SGK and to establish how
this protein kinase(s) is regulated
by PtdIns(3,4,5)P3. It is also
becoming obvious that the
information obtained by the
overexpression of constitutively
active and dominant negative
mutants of protein kinases is not
providing physiologically reliable
results and that new genetic and
pharmacological approaches are
needed to identify the substrates
of each of the individual insulin-
regulated protein kinases and to
establish their roles in mediating
insulin-dependent responses.
Another key challenge will be to
define the mechanism by which
PKB and the activation of TC10
trigger the translocation of
GLUT4 from its intracellular
stores to the plasma membrane.
Although our understanding of
the insulin signal transduction
pathway is far from being
complete, our current knowledge
of this pathway provides a
framework for the development
of novel drugs to treat diabetes.
For example a drug that could
mimic PtdIns(3,4,5)P3 would be
expected to promote glucose
uptake, glycogen synthesis and
stimulate protein synthesis in
tissues of diabetic patients.
Recent studies have also
demonstrated that inhibitors of
GSK3, do indeed mimic the
effects of insulin on this enzyme
in cell lines and promote the
uptake of glucose from the blood
and its conversion to glycogen. If
drugs that mimic the effect that
insulin has on its signalling
pathway are orally effective, it is
possible that these could be
used to treat type 1, as well as
type 2 diabetes, and so reduce or
replace the need for daily insulin
injections.
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Figure 2. PtdIns(3,4,5)P3 regulates the activation of PKB, S6K and SGK.
In this model of how PKB, S6K and SGK are phosphorylated at their T-loop, PDK1
activity is not directly activated by insulin or other agonists that elevate PtdIns(3,4,5)P3
levels. This is consistent with the experimental observation that PDK1 is constitutively
active in cells. Instead, it is the substrates of PDK1 that are converted into forms that
can be phosphorylated by PDK1. In the case of PKB, the interaction of PKB with
PtdIns(3,4,5)P3 at the plasma membrane converts PKB into a substrate for PDK1. In the
case of S6K and SGK which do not possess pleckstrin homology domains and cannot
interact with PtdIns(3,4,5)P3, this is achieved by the phosphorylation of these enzymes
at their hydrophobic motif by an unknown mechanism which generates a docking site
for PDK1.



























Activation of a H-motif kinase?
Inhibition of a H-motif phosphatase?
